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Bacterial membrane activity of a-peptide/b-peptoid
chimeras: Influence of amino acid composition and
chain length on the activity against different
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Abstract
Background: Characterization and use of antimicrobial peptides (AMPs) requires that their mode of action is
determined. The interaction of membrane-active peptides with their target is often established using model
membranes, however, the actual permeabilization of live bacterial cells and subsequent killing is usually not tested.
In this report, six a-peptide/b-peptoid chimeras were examined for the effect of amino acid/peptoid substitutions
and chain length on the membrane perturbation and subsequent killing of food-borne and clinical bacterial
isolates.
Results: All six AMP analogues inhibited growth of twelve food-borne and clinical bacterial strains including
Extended Spectrum Beta-Lactamase-producing Escherichia coli. In general, the Minimum Inhibitory Concentrations
(MIC) against Gram-positive and -negative bacteria were similar, ranging from 1 to 5 μM. The type of cationic
amino acid only had a minor effect on MIC values, whereas chain length had a profound influence on activity. All
chimeras were less active against Serratia marcescens (MICs above 46 μM). The chimeras were bactericidal and
induced leakage of ATP from Staphylococcus aureus and S. marcescens with similar time of onset and reduction in
the number of viable cells. EDTA pre-treatment of S. marcescens and E. coli followed by treatment with chimeras
resulted in pronounced killing indicating that disintegration of the Gram-negative outer membrane eliminated
innate differences in susceptibility. Chimera chain length did not influence the degree of ATP leakage, but the
amount of intracellular ATP remaining in the cell after treatment was influenced by chimera length with the
longest analogue causing complete depletion of intracellular ATP. Hence some chimeras caused a complete
disruption of the membrane, and this was parallel by the largest reduction in number of viable bacteria.
Conclusion: We found that chain length but not type of cationic amino acid influenced the antibacterial activity
of a series of synthetic a-peptide/b-peptoid chimeras. The synthetic chimeras exert their killing effect by
permeabilization of the bacterial cell envelope, and the outer membrane may act as a barrier in Gram-negative
bacteria. The tolerance of S. marcescens to chimeras may be due to differences in the composition of the
lipopolysaccharide layer also responsible for its resistance to polymyxin B.
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Background
Antimicrobial peptides (AMPs) are host defence molecules
that constitute an essential part of the innate immune sys-
tem among all classes of life [1]. Most AMPs permit the
host to resist bacterial infections by direct killing of invad-
ing bacteria or other microorganisms, however, many
AMPs are also immuno-modulatory and thus enhance the
host defence against pathogens [2-5].
In addition to their natural role in combating infections,
AMPs are recognized as promising alternatives to conven-
tional antibiotics for which development of resistance has
become an ever-increasing concern [6-8]. Peptide based
drugs are often hampered by a rapid in vivo degradation,
however, this may be circumvented by stabilizing natural
AMPs by single-site substitutions or by designing novel
synthetic analogues with an altered backbone that confers
complete stability to the compounds. Careful investigation
of structure-activity relationships may eventually allow
design of optimised antimicrobial compounds with high
activity and minimal side effects [9-15].
Many AMPs fold into an amphipathic structure, and it
is believed that this topology enables pore formation or
disintegration of bacterial cell membranes leading to bac-
terial cell death. The amphipathic properties usually
include cationic patches that promote interaction with
the anionic bacterial membrane as well as hydrophobic
patches that favor integration into the membrane. Since
this is the most common mode of action for AMPs there
has been an intense focus on their ability to adapt an
amphipathic conformation [16,17]. In particular, design
of peptides with a high propensity to fold into a helical
amphipathic conformation has attracted considerable
interest [13,18-20].
We have previously described a synthetic approach for
design of a-peptide/b-peptoid chimeras possessing a
design with alternating N-alkylated b-alanine (b-peptoid)
and a-amino acid units (Figure 1). In addition, prelimin-
ary investigations showed that such peptidomimetics
constitute a novel subclass of proteolytically stable anti-
microbial compounds [21-23]. This design displays chiral
unnatural b-peptoid residues that appear to contribute
with structure-promoting effects and lipophilicity, while
strongly cationic properties and intramolecular hydrogen
bonding capacity are introduced via the a-amino acids
lysine and/or homoarginine [24]. The precise secondary
structure of these chimeras still remains to be elucidated,
nevertheless, circular dichroism (CD) spectroscopy
clearly indicates the presence of some degree of second-
ary structure [22,23]. Interestingly, a higher degree of
secondary structure was found for analogues containing
chiral side chains in the b-peptoid units (i.e. compounds
2 and 3 in Figure 1) as compared to chimeras with achiral
b-peptoid residues (i.e. compound 1 in Figure 1) [22], but
the effect of this on antibacterial activity remains largely
unresolved [23].
The membrane-destabilizing effects of the chimeras
have only been investigated in model liposomes pre-
pared from phosphatidylcholine, a phospholipid found
Figure 1 Chemical structure of the six a-peptide/b-peptoid
chimeras
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predominantly in eukaryotic cells, and several of the chi-
meras permeabilized such liposomal membranes [24].
Most studies on membrane activity of antimicrobial
peptides have in fact been performed on model mem-
branes [25-28] while the effects on cell membranes of
viable bacteria have often not been tested. Also, the
effect of membrane permeabilization on killing of bac-
teria has not been tested [27].
Here, we test the antibacterial effect of six chimeras
against a spectrum of bacterial strains that include several
important clinical and food-borne pathogens. The main
purpose was to examine how the type of cationic amino
acid and sequence length affected the antibacterial activity
and to correlate this to a potential membrane-related
mode of action in viable bacteria.
Part of this work was presented at the 50th InterScience
Conference on Antimicrobial Agents and Chemotherapy
in Boston 12-15th of September 2010.
Methods
Bacterial strains and culture conditions
Initial activity experiments were carried out with twelve
strains from seven bacterial species representing com-
mon laboratory strains and clinical strains derived from
both food-borne and nosocomial infections (Table 1).
Stock cultures were stored at -80°C in 4% (w/v) glycerol,
0.5% (w/v) glucose, 2% (w/v) skimmed milk powder and
3% (w/v) tryptone soy powder. All experiments were
carried out with bacteria incubated for one night (i.e.
approximately 18 hours) at 37°C. Experiments were per-
formed in cation-adjusted Mueller Hinton II broth
(MHB) (Becton Dickinson 212322) adjusted to pH 7.4
or Tryptone Soy Broth (TSB) (Oxoid CM0129) for the
ATP leakage assays. Brain Heart Infusion (BHI)
(CM1135) with agar (VWR 20768.292) 1.5% as gelling
agent was used throughout for colony plating.
Peptide synthesis and selection
a-Peptide/b-peptoid chimeras consisting of alternating
repeats of natural cationic a-amino acids and synthetic
lipophilic b-peptoid residues were prepared by solid-phase
synthesis as previously described [21,22]. Six chimeras
were investigated in this study. The possible differences in
sensitivity of different bacterial species were evaluated by
testing the analogues 1, 2 and 3, distinguished by different
degrees of chirality and type of cationic amino acid. Addi-
tionally, the mixed series 4a, 4b and 4c, differing only in
the chain length, was used for evaluating the effect of this
on antimicrobial activity (Figure 1). Compounds 1, 2 and 3
have been described previously [23,24,29], while the series
4a, 4b and 4c were synthesized using the already estab-
lished synthesis protocols involving known dimeric
building blocks [21,22]. The identity of the primary pepti-
domimetic sequences 4a, 4b and 4c were confirmed by
high-resolution MS (Bruker MicroTOF-Q LC mass spec-
trometer equipped with an electrospray ionization source):
compound 4a, (m/z) [M+4H]4+ obsd. = 339.9727 (calcd. =
339.9719, ΔM 2.3 ppm); compound 4b, (m/z) [M+5H]5+
obsd. = 402.0614 (calcd. = 402.0608, ΔM 1.4 ppm); com-
pound 4c, (m/z) [M+6H]6+ obsd. = 443.2880 (calcd. =
443.2879, ΔM 0.2 ppm). Peptides were solubilized to
a stock of 10 mg/mL in sterile MilliQ water and stored
at -20°C.
Determination of Minimum Inhibitory Concentration (MIC)
and Minimum Bactericidal Concentration (MBC)
The Minimum Inhibitory Concentration (MIC) of the
chimeras was determined against the spectrum of bac-
teria using the microdilution method according to
guidelines of the Clinical and Laboratory Standards
Institute (CLSI) [30]. Chimera 1:2 serial dilutions were
prepared from 1,024 μg/mL stock solutions to give a
final range of 512-0.5 μg/mL in the wells. This corre-
sponds to a final range of 144 to 0.14 μM for the heavi-
est chimera (i.e. chimera 4c) and of 282 to 0.27 μM for
the lightest chimera (i.e. chimera 4a). Colonies grown
overnight (i.e. approximately 18 hours) on BHI agar
were suspended in 0.9% saline to give a turbidity of 0.13
at OD546 (approximately 1 × 10
8 CFU/mL), and then
diluted in MHB pH 7.4 to a final concentration of 5 ×
105 CFU/mL in each well. Following CLSI guidelines the
media for testing of Listeria monocytogenes strains were
supplemented with 2.5% lysed horse blood. Polypropy-
lene plates (Nunc 442587) were used to minimize pep-
tide binding and incubation time was 18-20 hours at
37°C. MIC was determined in a minimum of two tech-
nical replicates as the lowest concentration of the
Table 1 Origin and reference of bacterial strains used in
the present study
Origin Ref
S. aureus 8325-4 Wildtype [59]
K. pneumoniae ATCC 13883 Human, clinical -
S. marcescens ATCC 8100 Human, clinical -
E. coli ATCC 25922 Wildtype -
E. coli MG1655 K-12 F- lambda- [60]
E. coli AAS-EC-009 Human, clinical a
E.coli AAS-EC-010 Human, clinical a
L. monocytogenes 4446 Human, clinical [61]
L. monocytogenes N53-1 Food processing [62]
L. monocytogenes EGD Wildtype b
V. vulnificus ATCCT Human, clinical -
V. parahaemolyticus ATCCT Human, clinical -
Susceptibility testing were carried out with a selection of twelve different
bacterial strains comprising common laboratory strains and clinical strains
derived from food-borne pathogens as well as pathogens responsible for
nosocomial infections. a ESBL-producing clinical samples from Danish patients
in 2007; b This strain was kindly provided by Werner Goebel, University of
Würzburg.
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peptide analogue where no visible growth was found.
The Minimum Bactericidal Concentration (MBC) was
determined by plating 10 μL of the suspension from the
first three wells without growth on BHI agar and incu-
bating these for 24 hours at 37°C. MBC was the lowest
concentration at which a 99.9% reduction in CFU/mL
was observed. Activity is expressed in μmol/L to enable
a direct comparison of analogues with different length
(= size).
Killing kinetics of Staphylococcus aureus and Serratia
marcescens
In vitro time-kill curves for chimera 1, 2 and 3 were
determined against S. aureus 8325 (MIC μM: chimera 1
5.9; chimera 2 2.8; chimera 3 18.7) and Serratia marces-
cens ATCC 8100 (MIC μM: chimera 1 46.8; chimera 2
45.5; chimera 3 150.0). These two bacterial strains
represent organisms susceptible and tolerant to the chi-
meras, respectively. The bactericidal effect of the three
chimeras was tested at MIC in two independent experi-
ments; additionally the effect of chimera 2 was tested at
¼ and 1/2 times MIC. In brief, a suspension prepared
from fresh overnight colonies as described above was
transferred to 2 mL PBS or cation-adjusted MHB with
chimera added (from a 10 × MIC solution) to give a
similar bacterial cell density as employed in the MIC
determination; the resulting suspension was then incu-
bated at 37°C, 300 rpm. Samples for colony determina-
tion were taken at 0, 1, 2, 4, 6 and 8 hours after
addition and transferred to a ten-fold dilution row.
Colony counts were determined after incubation for
24 hours at 37°C.
ATP leakage assay
Pore formation as caused by peptide addition was deter-
mined by measuring ATP leakage from the bacterial cell
using a bioluminescence assay [31]. The assay was used
to estimate differences between sub-typical chimeras 1, 2
and 3 on S. aureus and S. marcescens and to evaluate the
effect of chain length of mixed type chimeras 4a, 4b and
4c on S. aureus. In brief, bacteria were grown in TSB at
37°C for 24 hours and then re-inoculated in TSB at 37°C
for 6-8 hours until an absorbance at 546 nm of 2.5 for
S. aureus and 2.0 for S. marcescens and then harvested
(10 min at 2,000 × g). The bacteria were grown to a high
absorbance since a high concentration of bacteria was
necessary in order to get a measurable response in the
ATP leakage assay. Cells were washed once in 50 mM
potassium phosphate buffer (pH 7.0) and once in 50 mM
HEPES buffer (pH 7.0), before the pellet was resuspended
in HEPES buffer to an OD546 ~ 10, and then stored on
ice. Before chimera addition bacteria were pre-incubated
with 0.2% (w/v) glucose to energize the cells. In general
a chimera dose of 1000 μg/mL (corresponding to
280-552 μM for all chimeras) was used for all assays;
however, for determining dose response curves additional
doses of 100 (28-55 μM), 250 (71-137 μM) and 500
(140-276 μM) μg/mL were tested, and only the immedi-
ate release was noted. Total ATP and extracellular ATP
were determined with a luminometer (Pharmacia Biotech
Novaspec II Visible Spectrophotometer). Intracellular
volumes [32] of S. aureus and S. marcescens (0.85 μm3
and 1.7 μm3, respectively) were subtracted from the total
volume before calculating the extracellular ATP concen-
tration; the intracellular ATP concentration could then
be calculated from this and the total ATP. ATP leakage
kinetics was determined on a bacterial suspension pre-
pared as above. Samples were taken at time 0, 5, 10, 20,
30 and 60 minutes and viable counts determined. Both
the ATP leakage assay and killing kinetics performed
under the same assay conditions were performed in two
independent experiments.
Results
Based on our previously published work on a-peptide/
b-peptoid chimeras [23,24,29] we selected six com-
pounds for the present study. Our main purpose was to
examine the influence of the type of cationic amino
acid and chain length on antibacterial activity and speci-
ficity. Also we aimed at elucidating the mechanism of
action against live bacterial cells and determine if this
(membrane perturbation) was influenced by the chimera
structural characteristics. We measured ATP leakage
from chimera-treated cells as an indication of mem-
brane pertubation. Comparing the ATP leakage with
time-kill studies allowed us to establish if there was a
direct correlation between permeabilization of the mem-
brane and killing of bacterial cells.
MIC and MBC against clinical and food-borne pathogens
Twelve strains representing seven bacterial species were
tested for their susceptibility to the peptide analogues. The
analogues exhibited a broad-spectrum activity with no dis-
tinct differences between Gram-positive and -negative
bacteria (Table 2). Five of the six chimeras had a strong
antibacterial effect with MIC values below 5 μM. Impor-
tant food-borne pathogens were included in the suscept-
ibility assay panel. Thus, three L. monocytogenes strains
representing both a clinical lineage 1 strain (strain 4446)
and a persistent lineage 2 strain from a food-processing
plant (strain N53-1) as well as clinical isolates of V. vulnifi-
cus and V. parahaemolyticus were examined.
The MIC values of chimeras 1, 2 and 3 were similar,
indicating that the b-peptoid side chain chirality (i.e. 1 vs.
2) had no effect on antibacterial activity and that the 12-
meric homoarginine (hArg) based sequence 2 was likely
equalled by the longer 16-meric lysine-containing analo-
gue 3. Generally, low MIC values were found for these
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three compounds, however, the activity of chimera 3 was
slightly lower than for chimera 1 and 2 against some
of the bacteria i.e. S. aureus, K. pneumoniae and S.
marcescens.
Chimeras 4a, 4b and 4c all have a 1:1 mixture of Lys and
hArg residues, but differ in length (8-16 residues), and this
had a marked effect on their antibacterial activity. The pat-
tern was the same against all bacterial strains tested. The
longest of the three, chimera 4c, was the most active com-
pound with MIC values of 1.1-2.2 μM against the food-
borne pathogens L. monocytogenes and Vibro spp. Chimera
4c was also active against the clinical strains of E. coli,
S. aureus and K. pneumoniae with MIC values in the
range of 2.2-9.0 μM (Table 2). Chimera 4b, with a length
of 12 residues, was less antibacterial with MIC values
approximately 2-3 times higher than those of the 16-mer
4c (Table 2). Chimera 4a being only half the length of chi-
mera 4c was the least antibacterial as the MIC values were
15-70 times higher than those of chimera 4c (Table 2).
Thus, the relative increase in activity was much larger for
elongation with a third repeating unit (i.e. from 8-mer 4a
to 12-mer 4b), than the further elongation of 4b with a
fourth repeating unit to afford 4c, revealing the minimally
required length of an active AMP analogue to be approxi-
mately 12 residues.
Two Extended Spectrum Beta-Lactamase (ESBL)-pro-
ducing E. coli clinical isolates (AAS-EC-009 and AAS-
EC-010) were included to determine if this antibiotic
resistance affected chimera sensitivity. However, the
chimeras were as effective against these strains as
against non-ESBL strains indicating that resistance
mechanisms conferring resistance to conventional anti-
biotics do not diminish the activity of the present pep-
tidomimetics. Interestingly, S. marcescens, which is
known to be intrinsically resistant to other antimicro-
bial peptides, was tolerant to all six chimeras (MICs
above 46 μM; Table 2), and it most likely possesses
resistance mechanisms that are different from those
present in the two multi-resistant E. coli strains.
All six chimeras had a Minimum Bactericidal Concen-
tration (MBC) equal to or double the MIC. The high
similarity between the MIC and MBC values indicates
that the chimeras exhibit a bactericidal mode of action.
Killing kinetics in two bacteria with different susceptibility
S. marcescens was the only bacterial strain tested that was
tolerant to the a-peptide/b-peptoid chimeras. The strain
is the only one considered intrinsically resistant to the
polymyxin group of AMPs, and this could explain its
resistance to our peptidomimetics. If so, this would indi-
cate that a very similar resistance mechanism was
responsible for the observed decrease in susceptibility.
Therefore we performed a comparative mechanistic
study that also included S. aureus and E. coli as suscepti-
ble reference strains.
We exposed S. aureus and S. marcescens to peptidomi-
metics 1, 2 and 3 at three different concentrations in
MHB as well as at their MIC concentration in PBS buffer
in order to determine whether these chimeras were only
active against growing bacterial cells. S. marcescens was
killed rapidly by chimera 2 (Figure 2A), and the lethal
effect was clearly concentration-dependent (Figure 2C).
In contrast, S. aureus was killed more slowly and with a
less pronounced effect of dose (Figure 2B and 2D). Treat-
ment of S. marcescens with chimera 2 at its MIC caused a
2 log decrease in the number of viable bacteria within the
first hour after which cell numbers declined over the
next 5 hours. When the bacteria were treated with the
chimera in PBS, the killing occurred very rapidly and no
viable cells remained after the first hour. When S. aureus
was treated with chimera 2 at the MIC in MHB, the
number of viable cells did not decrease until after 6
Table 2 Minimum Inhibitory Concentration (μM) of the six a-peptide/b-peptoid chimeras in the present study
Chimera 1 Chimera 2 Chimera 3 Chimera 4a Chimera 4b Chimera 4c
S. aureus 8325 5.9 2.8 18.7 141.2 23.8 4.5
K. pneumoniae ATCC 13883 1.5 2.8 37.5 282.4 23.8 9.0
S. marcescens ATCC 8100 46.8 45.5 150.0 > 282.4 190.3 71.8
E. coli ATCC 25922 1.5 2.8 9.4 141.2 3.0 2.2
E. coli MG1655 1.5 2.8 4.7 141.2 5.9 2.2
E. coli AAS-EC-009 1.5 2.8 9.4 141.2 11.9 4.5
E.coli AAS-EC-010 1.5 1.4 9.4 141.2 3.0 2.2
L. monocytogenes 4446 2.9 1.4 1.1 70.6 3.0 1.1
L. monocytogenes N53-1 2.9 2.8 1.1 70.6 5.9 1.1
L. monocytogenes EGD 1.5 2.8 1.1 70.6 3.0 1.1
V. vulnificus ATCCT 1.5 1.4 2.3 35.3 3.0 2.2
V. parahaemolyticus ATCCT 1.5 1.4 2.3 70.6 3.0 1.1
Minimum Inhibitory Concentration of the six peptidomimetics in this study against the spectrum of bacteria expressed in μM. Values were obtained from a
minimum of two independent trials. The Minimum Bactericidal Concentration (MBC) was in all assays equal to or a maximum of one two-fold higher than the
MIC value indicating a bactericidal mode of action.
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hours, however, when treated in PBS, viable cell numbers
decreased with log 2 after 4 hours (Figure 2B). Even
though a slightly decreased growth rate was observed for
S. aureus upon treatment with concentrations below
MIC as compared to the control, a concentration close to
the MIC value was needed to completely inhibit growth
of the culture (Figure 2D). In comparison, as low as ¼
MIC resulted in a reduction in cell number of S. marces-
cens (Figure 2C) revealing a more pronounced concentra-
tion-dependent killing for this bacterium.
Since the MIC value found for S. marcescens was consid-
erably higher than that seen for S. aureus, we performed
time-kill on E. coli, which exhibited a similar susceptibility
in terms of MIC to that of S. aureus, to test if the rapid
lethal effect against S. marcescens was due to the higher
concentrations of peptidomimetics (E. coli ATCC 25922
MIC μM: chimera 1 1.5; chimera 2 2.8; chimera 3 9.4).
However, a rapid killing effect was also found for this bac-
terial species (data not shown) ruling out that the elevated
concentrations solely could be responsible for the high
killing rate seen for S. marcescens.
Membrane perturbation effects in two bacteria with
different sensitivity
Killing kinetics often reflect the mode of action, and we
hypothesized that differences between S. aureus and S.
marcescens regarding their sensitivity and time-kill
might be due to different modes of interaction with the
peptidomimetics. Therefore, an ATP bioluminescence
assay was employed to determine (i) whether cell envel-
ope perturbation was involved in the antibacterial effect,
and (ii) if so, whether the organisms differed in the
degree of ATP leakage.
Chimera 1, 2 and 3 caused leakage of ATP from both S.
aureus and S. marcescens, but all three peptidomimetics
gave rise to an ATP leakage from S. aureus that was sub-
stantially larger than that from S. marcescens (see Figure
3 for results with chimera 1). The intracellular ATP con-
centration rapidly approached zero for both bacteria
within the first few minutes, whereas the extracellular
ATP concentration increased more rapidly during the
first minutes for S. aureus (~20 μM) than for S. marces-
cens (~5 μM). To examine if this could be due to the fact
Figure 2 Killing kinetics of chimera 2 against S. marcescens (A+C) and S. aureus (B+D) displayed as mean number of viable cells with
standard error of the mean (SEM). The assays were performed in two independent experiments. Time-kill of the chimera was determined at MIC in
MHB (grey solid) and PBS (grey punctuated) and compared to MilliQ-treated control in MHB (black solid) and PBS (black punctuated) for S. marcescens
(A) and S. aureus (B). The effect of chimera concentration on time-kill was determined in MHB at ¼ MIC (dark grey), 1/2 MIC (light grey) and MIC (black
punctuated) and compared with MilliQ-treated control (black solid) for S. marcescens and (C) and S. aureus (D).
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that the two bacteria were treated with the same dose
despite their very different MIC values, we determined
their dose response curves. For both bacteria a minimum
chimera dose of 500 μg/mL (i.e. 145-180 μM) was needed
to obtain the maximum immediate response (data not
shown) ruling out that the rapid release of ATP from
S. aureus seen in Figure 3A is due to a higher concentra-
tion/MIC ratio than employed for S. marcescens.
To investigate if the degree of ATP leakage from the
bacterial cell corresponded to the simultaneous decrease
in the number of viable cells (i.e. if S. marcescens cells on
the basis of their elevated MIC were in fact able to sur-
vive even after a moderate ATP leakage) we determined
time-kill under exactly the same conditions as the ATP
bioluminescence assay had been performed. Irrespective
of which of the three chimeras that were used, both bac-
teria were reduced 2-3 log from an initial value of log
~9.5 per mL within the first 20 minutes before the ATP
leakage tailored off and no further decrease in viable
count was seen for up to 60 minutes (not shown). This
indicates that the degree of ATP leakage from the two
bacteria (i.e. the concentration of the extracellular ATP)
does not reflect differences in viability. No reduction in
the number of viable bacteria was seen for the control
(not shown), and the intracellular concentration of ATP
did not change (Figure 3A and 3B).
Although there was no systematic difference in the
MIC values between Gram-positive and -negative bac-
teria, we speculated that the Gram-negative outer mem-
brane could act as a barrier to the penetration of AMPs,
since polymyxin B resistance in S. marcescens has been
linked to induced changes in the amount and composi-
tion of lipopolysaccharide (LPS) in the outer membrane
[33]. Moreover, similar resistance-conferring membrane
alterations have also been seen for other bacteria in
response to polymyxin B treatment [34-36]. Accordingly,
we studied how a membrane-destabilizing pre-treatment
of S. marcescens, E. coli and S. aureus with the divalent
metal cation-chelating agent EDTA would affect the kill-
ing caused by chimera 1. In these experiments we used a
non-lethal 0.5 mM concentration of EDTA together with
the non-lethal 1.5 μM concentration of the tested AMP
analogue. A slight reduction in the number of viable cells
corresponding to 0.5 log was seen for S. aureus when
treated with chimera 1 alone while E. coli and S. marces-
cens were reduced with 1.5 log (data not shown). No dis-
cernable difference in the number of viable cells
remaining was observed between S. aureus treated suc-
cessively with EDTA and peptidomimetic and S. aureus
treated only with the peptidomimetic. In contrast, cell
numbers of both S. marcescens and E. coli were reduced
with 4-5 log from an initial value of log ~5.5 within the
first 4 hours (not shown) upon treatment with a sub-
lethal EDTA concentration together with the chimera.
This indicates that the intact outer membrane indeed
appears to act as a protective barrier against the antibac-
terial chimeras.
The effect of chimera chain length on membrane
perturbation activity
Peptidomimetics 4a, 4b and 4c consist of the same repeat-
ing unit of four residues (Figure 1; n = 2, 3 and 4, respec-
tively), and thus differ only in length. The MIC values
increased dramatically when going from 8-mer (4a) to 12-
mer (4b) while further elongation to 16-mer (4c) only led
to a slight enhancement in potency (Table 2). Hence, we
were intrigued to establish whether mechanistic differ-
ences could explain this strong correlation.
Figure 3 Chimera-induced ATP leakage in S. aureus (A) and S. marcescens (B) after treatment with 1000 μg/mL chimera. The assays
were performed in two independent experiments. Mean (SEM) intracellular (IC, solid line) and extracellular (EC, punctuated line) ATP
concentration for S. aureus cells (figure A, grey lines) and S. marcescens cells (figure B, grey lines) treated with chimera 1 compared to MilliQ-
treated control (black lines).
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We determined ATP leakage from S. aureus when trea-
ted with chimeras 4a, 4b and 4c to evaluate the effect of
chain length on the extent of pore formation or membrane
disintegration caused by the chimeras. Peptidomimetic-
induced ATP leakage was markedly different for S. aureus
treated with chimera 4a (Figure 4A) as compared to
S. aureus treated with chimera 4c (Figure 4C). The immedi-
ate ATP release was approximately 15 μM for both pepti-
domimetics; however, the intracellular ATP concentration
remained at approx. 5 μM, when the bacterial cells were
treated with the shorter analogue 4a, whereas cells treated
with chimera 4c were immediately depleted of intracellular
ATP. Since the leakage was continuous it seemed that the
cells were able to maintain the ATP production. S. aureus
cells treated with the intermediate length 12-meric chimera
4b had the same leakage pattern as induced by chimera 4a.
Dose-response profiles were also determined (as already
described in the previous section), and despite differences
in MIC values between chimeras 4a and 4c, both reached
the immediate maximum ATP release at 500 μg/mL (i.e.
276 μM and 140 μM, respectively). Likewise, the observed
ATP release was similar immediately upon treatment with
either chimera 4a or 4c, and again cells treated with chi-
mera 4a were able to maintain a low intracellular level of
ATP.
The fact that some ATP remained in the cell after
treatment with chimera 4a could point to an incomplete
disruption of the bacterial cell membrane as compared to
bacterial cells treated with chimera 4c. To determine if
an intracellular ATP concentration of 5 μM had a physio-
logical effect and would allow the bacterial cells to sur-
vive, time-kill was again performed under exactly the
same conditions as used in the ATP assay to allow com-
parison of ATP leakage with killing kinetics. After treat-
ment with chimera 4c, cell numbers were reduced with 2
log within the first 20 minutes (Figure 4D), however,
Figure 4 The effect of chimera chain length on ATP release from S. aureus after treatment with 1000 μg/mL chimera and the
corresponding change in the number of viable cells after treatment with chimera 4a (A+B) or chimera 4c (C+D). The assays were
performed in two independent experiments. Mean (SEM) intracellular (IC, solid line) and extracellular (EC, punctuated line) ATP concentration for
cells treated with chimera 4a (figure A, grey lines) or 4c (figure C, grey lines) compared to MilliQ-treated control (black lines). Mean (SEM)
number of viable cells after addition of chimera 4a (figure B, grey line) or 4c (figure D, grey line) compared to MilliQ-treated control (black line).
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after treatment with chimera 4a (Figure 4B) or chimera
4b (not shown) no killing was observed. The pool of
intracellular ATP in the peptidomimetic-treated bacterial
cells can therefore, as opposed to the amount of leaked
ATP, be considered as indicative for the number of viable
cells remaining.
Discussion
The aim of this study was to determine the mechanism
of action for a series of peptidomimetics, and specifically
we set out to probe the importance of amino acid com-
position and chain length for antibacterial activity. We
included a strain intrinsically resistant to AMPs, and
addressed whether killing kinetics and AMP mechanism
of action in viable bacteria could provide a mechanistic
explanation for the much lower susceptibility of S. mar-
cescens as compared to the more sensitive bacteria.
We examined the effect of having exclusively lysine or
homoarginine cationic residues as well as of substituting
the chiral b-peptoids with achiral counterparts as repre-
sented by the a-peptide/b-peptoid chimeras 1, 2 and 3
(Table 2). All three peptidomimetics had MIC values of 1-
3 μM against most bacterial strains, which compared to
many natural AMPs is a high activity [14,19,37-39].
Noticeably, a considerably lower activity against S. aureus
and K. pneumoniae was observed for the lysine-containing
chimera 3 (6-13 fold) as compared to the homoarginine-
based chimera 2, while only a slightly lower activity of chi-
mera 3 (2-7 fold) was seen compared to chimera 2 when
tested against E.coli. The reduced chirality in chimera 1
did not give rise to any significant loss of activity as com-
pared to chimera 2. In a preliminary antimicrobial charac-
terization these peptidomimetics were tested against four
common bacteria and a fungus [23], whereas the present
study also included important food-borne pathogens L.
monocytogenes, V. vulnificus and V. parahaemolyticus
against which the chimeras also were active (Table 2).
Additionally we investigated the effect of chain length
on activity by studying a series of three peptidomimetics
(i.e. chimera 4a, 4b and 4c based on the same repeating
unit of four residues), which indicated that the mini-
mally required length for an active peptidomimetic is
around 12 residues (Table 2). It has previously been
reported that 14 amino acids is the minimal sequence
required for an active antimicrobial peptide [25], how-
ever, this and other studies focused on the effect of
length on helicity which implies structural restrictions
in the design to enable it to span the lipid bilayer
[26,40]. Also, it is clearly established that the low activity
earlier reported for the shorter homologues of chimera 3
(e.g. the 12-mer exhibited almost no activity [23]) may
be compensated for by a longer sequence. Chimera 4c
corresponds to the analogue where half of the lysines in
chimera 3 are replaced by homoarginines, and similarly
chimera 4b may be considered an analogue derived
from chimera 2 by exchanging half of the homoargi-
nines with lysines. Comparison of the activities found
for these two pairs indicates that a high content of
homoarginines generally induces a somewhat higher
potency; especially, the activity against S. aureus and
K. pneumoniae is clearly promoted by a prevalence of
guaninido-functionalized residues.
A high activity was also found against two isolates of
ESBL-producing E. coli (AAS-EC-09 and AAS-EC-010)
indicating that resistance towards conventional antibiotics
do not affect the sensitivity towards these peptidomi-
metics, further supporting a different mode of action.
Many AMPs exhibit a cell envelope-perturbing effect
[41-43], and hence their target is different from traditional
antibiotics of which many act by inhibiting cell wall synth-
esis or on intracellular targets [44-46]. Notably, S. marces-
cens was the only bacterial strain that proved tolerant to
the peptidomimetics, and thus must harbour specific resis-
tance mechanisms involving induction of changes in the
cell envelope.
Time-kill experiments showed that S. marcescens was
killed more rapidly than the susceptible strain of S. aur-
eus when treated with chimera 1, 2 or 3 at concentrations
close to their MIC values (Figure 2). Polymyxin B and
other cationic AMPs may at high doses in themselves act
like chelating agents allowing them to penetrate the
outer membrane [47,48], however, a noticeable effect was
also seen against S. marcescens at concentrations lower
that the MIC value (Figure 2C). Rapid killing was also
demonstrated for E. coli exposed to the peptidomimetics,
indicating that this could be a phenomenon associated
with Gram-negative bacteria. Shorter exposure times
caused a significant killing of Gram-negative bacteria
when treated with some a-helical AMPs that act by per-
meabilization of the membrane [37]. Another explanation
for the observed differences in the rate of killing could be
that either the degree or mode of membrane disruption
differs among bacteria i.e. the chimeras may exert their
effect by a combination of several mechanisms. The fact
that cell membranes of different bacteria differs in lipid
composition [49] could influence the interaction between
phospholipids and AMPs. However, there is no unequi-
vocal evidence demonstrating that an AMP may exhibit
different pore-forming properties in different bacteria, as
the proposed co-existence of several disruption modes in
fact still is a topic of debate [50,51].
Many AMPs exert their antibacterial effect by interac-
tions with the bacterial cell membrane [38,41,52] invol-
ving pore formation or membrane disintegration that in
turn causes leakage of the cell contents, which ultimately
leads to cell death. Nevertheless, there is a growing
amount of indirect evidence that the mechanisms of
some very potent AMPs in fact involves an initial period
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of intracellular accumulation prior to the actual bacterial
killing indicating that they act on intracellular targets
[38,53,54]. To further investigate the effect of the present
peptidomimetics on the cell membrane in S. marcescens
and S. aureus and to determine how structural features
of these peptidomimetics might affect the potential mem-
brane-related mode of action we examined their ability to
cause leakage of intracellular compounds e.g. ATP. A
considerable body of data on the leakage of intracellular
compounds has already been obtained by using model
membranes thus confirming that many membrane-active
peptides indeed exert a permeabilizing effect [24-26,28].
These studies have, however, not demonstrated whether
there is a direct kinetic relationship between cell mem-
brane damage and loss of viability, and for this reason we
combined leakage assays with a time-kill experiment
under exactly the same conditions.
Treatment of both S. marcescens and S. aureus with
peptidomimetics 1, 2 and 3 caused leakage of ATP from
the bacterial cells with a similar simultaneous reduction in
the number of viable cells, and therefore we conclude that
even though S. marcescens is tolerant to the peptidomi-
metics their mode of action against this bacterium is simi-
lar to that of S. aureus. Earlier, chimera 3 was investigated
for its ability to induce calcein leakage in unilamellar lipo-
somes mimicking human cell membranes with a positive
response [24], but based on the consistent results in the
present work all three peptidomimetics are likely to per-
meabilize both model and bacterial membranes. Leakage
of intracellular compounds has been determined to be the
mode of action for many AMPs [55-57], but here we have
established this mode of action for a series of peptidomi-
metics. We conclude that variation of the type of cationic
amino acid (i.e. lysine versus homoarginine) did not have
an effect on the mode of action in viable bacteria.
Since S. marcescens was tolerant to all peptidomi-
metics tested, their mode of action must therefore
involve a target that is ultimately changed by resistance
mechanisms in this species. It is well-known that
S. marcescens is tolerant to the polymyxin group of
antimicrobials, and the main hypothesis is that this is
due to inherent changes in the composition of the LPS
of the Gram-negative outer membrane that acts as a
barrier [33]. We demonstrated that the outer mem-
brane also seems to play an important role in the tol-
erance of S. marcescens towards our chimeras as a
combined treatment including the chelating agent
EDTA resulted in a reduction in the number of viable
cells comparable to that seen for a more susceptible
Gram-negative strain of E. coli treated similarly (not
shown). This indicated that the innate differences in
susceptibility between the two Gram-negative species
could be completely eliminated after destabilization of
the outer membrane.
When designing new antimicrobial peptides it is gen-
erally accepted that a minimum length is required in
order for the peptide to span or transverse the cell
membrane. However, the majority of studies have
focused on optimizing the length of AMPs assuming it
to adopt a helical conformation [25,26,40]. By contrast,
due to their design with alternating hydrophobic and
cationic residues our peptidomimetics are not expected
to adopt an amphipathic helical active confirmation, but
rather an extended conformation with some degree of
secondary structure as indicated by analysis of their CD
spectra [22,23]. Recently, it has been shown that neither
global amphipathicity nor regular secondary structure
may be required for short peptides to effectively interact
with bacterial membranes [19,58], but the optimal
length of such peptides has not been rationalized by
mechanistic experiments. Only oligomers with a chain
length above 12 residues, i.e. the 16-meric peptidomi-
metic 4c were able to cause such a substantial leakage
of ATP that the number of viable cells were reduced
(Figure 4C and 4D). We attribute this to the inability of
chimeras 4a and 4b to produce a critical degree of
membrane disruption thus leaving a sufficient level of
intracellular ATP for the cells to survive (Figure 4A and
4B for chimera 4a).
This is to our knowledge the first time that the effect
of chain length has been investigated on the membrane-
perturbing activity of peptidomimetics without a domi-
nant secondary structure. Also, we believe that our
study is the first that directly, in a kinetic fashion, corre-
late membrane permeabilization with actual killing
kinetics.
Previously, the interaction of a-peptide/b-peptides chi-
meras with liposomal model membranes and murine
fibroblast was described [24]. Most recently, we investi-
gated their cytotoxicity and haemolytic activity towards
human HeLa cells and erythrocytes, respectively [23].
Besides confirming that members of this subclass of
peptidomimetics exhibit a broad antimicrobial activity
that includes resistant strains and food-borne pathogens,
the purpose of the present study was to undertake a
more detailed investigation of their mode of action. The
present contribution describes their interaction with
viable bacterial cells, and we found that these antimicro-
bial peptidomimetics have a mode of action involving
the cell membrane. The observed membrane disruption
depends strongly on chain length, and it may be
impeded if the outer membrane in a Gram-negative bac-
terium possesses an innate altered composition.
Conclusion
Several a-peptide/b-peptoid chimeras were bactericidal
against important food-borne and clinical pathogens
with MIC values in the range of 1-5 μM. We examined
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the effect of changing the ratio between amino- and
guanidino-functionalized cationic residues as well as the
influence of chain length on both antibacterial activity
and ATP leakage. Although, minor differences in the
antimicrobial profile of the chimeras may be ascribed to
the degree of chirality and/or type of cationic amino
acids, by far the most pronounced impact stems from
the chain length. Only one bacterial species, S. marces-
cens, was tolerant to the peptidomimetics most likely
due to the composition of its outer membrane; however,
the ATP leakage was as pronounced as seen for more
sensitive bacteria. We conclude that these synthetic anti-
microbial peptidomimetics exert their effect through
permeabilization of the cell membrane, and that this
corresponds to a simultaneous reduction in the number
of viable bacteria with the pool of intracellular ATP
being indicative of viability. This is the first time that a
relationship is established between permeabilization and
killing within a peptidomimetics library.
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